Chrome Plugin Live! Redefine the way you read FinTwit š Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
CBIO
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
globenewswire.com
7 hours ago
globenewswire.com
7 hours ago
globenewswire.com
7 hours ago
seekingalpha.com
11 hours ago
businesswire.com
16 hours ago
Relative Strength
CBIO
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Quote Panel
Key Metrics
Crescent Biopharma, Inc., an oncology company, develops therapies for cancer patients. Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat solid tumors. The company is headquartered in Waltham, Massachusetts.
NASDAQ
Unprofitable
Unprofitable
-0.31Ā ( -2.58%)
After-hours 11.74$
0.02 (0.17%)
Relative Strenght
15
Volume Buzz
-19%
Earning Acce
No
Dist 52w H.
81%Earnings Growth
YoY
Current
Estimates
Q3.23
N/A
-0.14
vsĀ -0.16
Q4.23
N/A
-0.14
vsĀ -0.19
Q1.24
N/A
-0.17
vsĀ -0.17
Q2.24
N/A
-0.16
vsĀ -0.13
Q3.24
N/A
-0.15
vsĀ -0.14
Q4.24
N/A
-0.11
vsĀ -0.14
Q1.25
N/A
-0.04
vsĀ -0.17
Q2.25
N/A
-4.93
vsĀ -0.16
Q3.25
N/A
-1.01
vsĀ -0.15
Q4.25
N/A
-1.10
vsĀ -0.11
Sales Growth
YoY
Current
Estimates
Q1.23
NA
NAĀ vsĀ NA
Q2.23
-100%
NAĀ vsĀ 75K
Q3.23
NA
NAĀ vsĀ NA
Q4.23
NA
10KĀ vsĀ NA
Q1.24
NA
NAĀ vsĀ NA
Q2.24
NA
NAĀ vsĀ NA
Q3.24
NA
NAĀ vsĀ NA
Q4.24
-100%
NAĀ vsĀ 10K
Q1.25
NA
NAĀ vsĀ NA
Q2.25
NA
NAĀ vsĀ NA
Return on Equity
QoQ
Q1.23
-17%
-0.17
vsĀ -0.24
Q2.23
-15%
-0.15
vsĀ -0.17
Q3.23
-20%
-0.20
vsĀ -0.15
Q4.23
-24%
-0.24
vsĀ -0.20
Q1.24
-37%
-0.37
vsĀ -0.24
Q2.24
-50%
-0.50
vsĀ -0.37
Q3.24
-86%
-0.86
vsĀ -0.50
Q4.24
-136%
-1.36
vsĀ -0.86
Q1.25
-69%
-0.69
vsĀ -1.36
Q2.25
-16%
-0.16
vsĀ -0.69
Institutionnal Ownership
QoQ
Q1.23
37
37
vsĀ 36
3%
Q2.23
29
29
vsĀ 37
-22%
Q3.23
32
32
vsĀ 29
10%
Q4.23
1
1
vsĀ 32
-97%
Q1.24
NA
NA
vsĀ NA
NA
Q2.24
NA
NA
vsĀ NA
NA
Q3.24
NA
NA
vsĀ NA
NA
Q4.24
1
1
vsĀ NA
NA
Q1.25
NA
NA
vsĀ NA
NA
Q2.25
28
28
vsĀ NA
NA
Forecast
2026-Revenue
47%2026-EPS
2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
26.00(121.84%)
Number of analyst
1
Last analyst upgrade/downgrade
Jefferies
initialisePrevious: Not converted
2025-08-25
Now: Buy
Wedbush
initialisePrevious: Not converted
2025-07-14
Now: Outperform
Cowen & Co.
downgradePrevious: Not converted
2024-07-26
Now: Hold
H.C. Wainwright
downgradePrevious: Not converted
2024-05-06
Now: Neutral